
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 6 April 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 5MB, 226 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
Export 122 results:
Author [ Title
Filters: Author is van Staa, T. P. [Clear All Filters]
“What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
, “Variability of antibiotic prescribing in patients with chronic obstructive pulmonary disease exacerbations: a cohort study”, BMC Pulm Med, vol. 13, p. 32, 2013.
, “Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: a retrospective cohort study”, Clin Ther, vol. 31, pp. 1707-15, 2009.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
, “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
, “Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy”, Neurology, vol. 66, pp. 1318-24, 2006.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, ,
“Supplementing electronic health records through sample collection and patient diaries: A study set within a primary care research database”, Pharmacoepidemiol Drug Saf, vol. 27, pp. 239-242, 2018.
, “Study of adverse outcomes in women using testosterone therapy”, Maturitas, vol. 62, pp. 76-80, 2009.
, “Smoking cessation interventions following acute coronary syndrome: a missed opportunity?”, Eur J Prev Cardiol, vol. 21, pp. 767-73, 2014.
, “Smoke-free legislation and the incidence of paediatric respiratory infections and wheezing/asthma: interrupted time series analyses in the four UK nations”, Sci Rep, vol. 5, p. 15246, 2015.
, “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
, “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
, “Shorter and longer courses of antibiotics for common infections and the association with reductions of infection-related complications including hospital admissions”, Clin Infect Dis, 2021.
, “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
, “Secular trends in fracture incidence in the UK between 1990 and 2012”, Osteoporos Int, vol. 27, pp. 3197-3206, 2016.
, “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.
, “Safety and efficacy of new oral anticoagulants and low-molecular-weight heparins compared with aspirin in patients undergoing total knee and hip replacements”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1245-1252, 2016.
, “Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients”, Thromb Haemost, vol. 106, pp. 968-77, 2011.
, “Risk of vertebral and non-vertebral fractures in patients with sarcoidosis: a population-based cohort”, Osteoporos Int, vol. 27, pp. 1603-1610, 2016.
, “Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK”, Osteoporos Int, vol. 29, pp. 467-478, 2018.
, “The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK”, Osteoporos Int, 2020.
, “Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database”, Cardiovasc Psychiatry Neurol, vol. 2013, p. 647476, 2013.
, “The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010”, Osteoporos Int, vol. 25, pp. 2555-63, 2014.
, “Risk of hip/femur fractures in patients using antipsychotics”, Bone, vol. 37, pp. 864-70, 2005.
, “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
, “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
, “Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study”, Bmj, vol. 345, p. e5085, 2012.
, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
, “Risk of community-acquired pneumonia in chronic obstructive pulmonary disease stratified by smoking status: a population-based cohort study in the United Kingdom”, Int J Chron Obstruct Pulmon Dis, vol. 12, pp. 2425-2432, 2017.
, “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
, “Resource utilization and outcomes in patients with atrial fibrillation: a case control study”, Appl Health Econ Health Policy, vol. 10, pp. 249-59, 2012.
, “Relationship between prescribing of antibiotics and other medicines in primary care: a cross-sectional study”, Br J Gen Pract, vol. 69, pp. e42-e51, 2019.
, “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
, “Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study”, J Antimicrob Chemother, vol. 72, pp. 2636-2646, 2017.
, “Quality of INR control and outcomes following venous thromboembolism”, Clin Appl Thromb Hemost, vol. 18, pp. 370-8, 2012.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment”, Br J Clin Pharmacol, vol. 78, pp. 649-59, 2014.
, “Prediction of cardiovascular risk using Framingham, ASSIGN and QRISK2: how well do they predict individual rather than population risk?”, PLoS One, vol. 9, p. e106455, 2014.
, “The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates”, Qjm, vol. 102, pp. 35-42, 2009.
,